Jordan Fishman, one of more than two dozen individuals connected to horse racing who were indicted last year on charges of misbranding and adulterating drugs, was sentenced on Monday to 15 months in prison by a federal judge, according to court documents. Fishman, 64, acknowledged during an earlier hearing that he manufactured products for MediVet Equine, a animal-products company owned by Seth Fishman, who was found guilty in a jury trial last week of two felony charges of conspiring to adulterate and misbrand drugs. The two Fishmans are not related. The 15-month sentence was within the recommendation issued by prosecutors, though the maximum sentence on the specific charge was three years. Fishman was also fined $100, and his sentence included one year of supervised release. Judge Mary Kay Vyskocil of the U.S. District Court for the Southern District of New York ruled that Fishman must surrender to federal authorities on May 9. Vyscokil recommended that Fishman be incarcerated at Devens, a minimum-security prison camp in Massachusetts. In a superseding indictment released last year, Fishman was accused of producing and distributing drugs to Thoroughbred and Standardbred trainers and other horsemen through MediVet. Among the drugs described in the indictment were purported “blood builders” and SGF-1000, the now notorious substance that was marketed as a performance-enhancing drug. In one wiretapped conversation produced by government prosecutors in the indictment, Fishman told the Thoroughbred trainer Navarro that he had “hundreds of products” and that most of them were “untestable,” meaning that they would not return positives in post-race drug tests. Fishman also told Navarro that he could create “customized” substances. Navarro was sentenced to five years in prison after entering a guilty plea to one felony charge of conspiring to adulterate and misbrand drugs. Among those charged and awaiting trial in the case is Jason Servis, the trainer of 2019 3-year-old champion Maximum Security. Servis is expected to go to trial late in the spring, provided he does not reach a plea agreement with U.S. prosecutors prior to the trial date.